Vitamin D and atherosclerosis

Current Opinion in Cardiology

Volumn 29, Issue 6, 2014, Pages 571-577

  Menezes, Arthur R ^a   Lamb, Marie C ^a   Lavie, Carl J ^a,b   DiNicolantonio, James J ^c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^c SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

Author keywords

Atherosclerosis; Cardiovascular disease; Vitamin D

Indexed keywords

VITAMIN D; VITAMIN;

ATHEROSCLEROSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; HUMAN; PRIORITY JOURNAL; REVIEW; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; BLOOD; COMPLICATION; RISK FACTOR;

ATHEROSCLEROSIS; HUMANS; RISK FACTORS; VITAMIN D; VITAMIN D DEFICIENCY; VITAMINS;

EID: 84927743612     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0000000000000108     Document Type: Review

References (82)

1. Lee JH, O'Keefe JH, Bell D, et al. Vitamin D deficiency: an important, common, and easily treatable cardiovascular risk factor? J Am Coll Cardiol 2008; 52:1949-1956.
2. Lips P. Worldwide status of vitamin D nutrition. J Steroid Biochem Mol Biol 2010; 121:297-300.
3. Norman PE, Powell JT. Vitamin D and cardiovascular disease. Circ Res 2014; 114:379-393.
4. Verdoia M, Schaffer A, Sartori C, et al. Vitamin D deficiency is independently associated with the extent of coronary artery disease. Eur J Clin Invest 2014; 44:634-642.
5. Wang L, Manson JE, Song Y, Sesso HD. Systematic review: vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med 2010; 152:315-323.
6. Kassi E, Adamopoulos C, Basdra EK, Papavassiliou AG. Role of Vitamin D in atherosclerosis. Circulation 2013; 128:2517-2531.
7. Rosen CJ, Adams JS, Bikle DD, et al. The nonskeletal effects of vitamin D: an Endocrine Society scientific statement. Endocr Rev 2012; 33:456-492.
8. Nemerovski CW, Dorsch MP, Simpson RU, et al. Vitamin D and cardiovascular disease. Pharmacotherapy 2009; 29:691-708.
9. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357:266-281.
10. Holick MF. The vitamin D epidemic and its health consequences. J Nutr 2005; 135:2739S-2748S.
11. Binkley N, Ramamurthy R, Krueger D. Low vitamin D status: definition, prevalence, consequences, and correction. Endocrinol Metab Clin North Am 2010; 39:287-301.
12. Alshahrani F, Aljohani N. Vitamin D: deficiency, sufficiency and toxicity. Nutrients 2013; 5:3605-3616.
13. Ogan D, Pritchett K. Vitamin D and the athlete: risks, recommendations, and benefits. Nutrients 2013; 5:1856-1868.
14. Heaney RP, Dowell MS, Hale CA, et al. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr 2003; 22:142-146.
15. Thacher TD, Clarke BL. Vitamin D insufficiency. Mayo Clin Proc 2011; 86:50-60.
16. Lavie CJ, Lee JH, Milani RV. Vitamin D and cardiovascular disease will it live up to its hype? J Am Coll Cardiol 2011; 58:1547-1556.
17. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004; 109 (Suppl 1):III27-III32.
18. Lavie CJ, Dinicolantonio JJ, Milani RV. Vitamin D and cardiovascular health. Circulation 2013; 128:2404-2406.
19. Merke J, Milde P, Lewicka S, et al. Identification and regulation of 1,25-dihydroxyvitamin D3 receptor activity and biosynthesis of 1,25-dihydroxyvitamin D3. Studies in cultured bovine aortic endothelial cells and human dermal capillaries. J Clin Invest 1989; 83:1903-1915.
20. Andrukhova O, Slavic S, Zeitz U, et al. Vitamin D is a regulator of endothelial nitric oxide synthase and arterial stiffness in mice. Mol Endocrinol 2014; 28:53-64.
21. Wang HJ, Cao JP, Yu JK, et al. Calbindin-D28K expression induced by glial cell line-derived neurotrophic factor in substantia nigra neurons dependent on PI3K/Akt/NF-kappaB signaling pathway. Eur J Pharmacol 2008; 595:7-12.
22. Petrofsky J, Alshahmmari F, Yim JE, et al. The interrelationship between locally applied heat, ageing and skin blood flow on heat transfer into and from the skin. J Med Eng Technol 2011; 35:262-264.
23. Wong MS, Delansorne R, Man RY, Vanhoutte PM. Vitamin D derivatives acutely reduce endothelium-dependent contractions in the aorta of the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol 2008; 295:H289-H296.
24. Duprez D, de Buyzere M, de Backer T, Clement D. Relationship between vitamin D3 and the peripheral circulation in moderate arterial primary hypertension. Blood Press 1994; 3:389-393.
25. Shi Y, Feletou M, Ku DD, et al. The calcium ionophore A23187 induces endothelium-dependent contractions in femoral arteries from rats with streptozotocin- induced diabetes. Br J Pharmacol 2007; 150:624-632.
26. Wong SL, Leung FP, Lau CW, et al. Cyclooxygenase-2-derived prostaglandin F2alpha mediates endothelium-dependent contractions in the aortae of hamsters with increased impact during aging. Circ Res 2009; 104:228-235.
27. Katusic ZS, Shepherd JT, Vanhoutte PM. Endothelium-dependent contractions to calcium ionophore A23187, arachidonic acid, and acetylcholine in canine basilar arteries. Stroke 1988; 19:476-479.
28. Miller VM, Vanhoutte PM. Endothelium-dependent contractions to arachidonic acid are mediated by products of cyclooxygenase. Am J Physiol 1985; 248:H432-H437.
29. Belton O, Byrne D, Kearney D, et al. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102:840-845.
30. Baker CS, Hall RJ, Evans TJ, et al. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol 1999; 19:646-655.
31. Schonbeck U, Sukhova GK, Graber P, et al. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 1999; 155:1281-1291.
32. Krishnan AV, Feldman D. Molecular pathways mediating the anti-inflammatory effects of calcitriol: implications for prostate cancer chemoprevention and treatment. Endocr Relat Cancer 2010; 17:R19-R38.
33. Wakasugi M, Noguchi T, Inoue M, et al. Vitamin D3 stimulates the production of prostacyclin by vascular smooth muscle cells. Prostaglandins 1991; 42:127-136.
34. Doran AC, Meller N, McNamara CA. Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler Thromb Vasc Biol 2008; 28:812-819.
35. Somjen D, Weisman Y, Kohen F, et al. 25-hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation 2005; 111:1666-1671.
36. Chen S, Law CS, Gardner DG. Vitamin D-dependent suppression of endothelin- induced vascular smooth muscle cell proliferation through inhibition of CDK2 activity. J Steroid Biochem Mol Biol 2010; 118:135-141.
37. Norman PE, Powell JT. Vitamin D shedding light on the development of disease in peripheral arteries. Arterioscler Thromb Vasc Biol 2005; 25:39-46.
38. Pierce R, Kolodzie M, Parks W. 1,25-Dihydroxyvitamin D3 represses tropoelastin expression by a posttranscriptional mechanism. J Biol Chem 1992; 267:11593-11599.
39. Kuroki Y, Shiozawa S, Kano J, Chihara K. Competition between c-fos and 1,25(OH)2 vitamin D3 in the transcriptional control of type1 collagen synthesis in MC3T3-E1 osteoblastic cells. J Cell Physiol 1995; 164:459-464.
40. Lin R, Amizuka N, Sasaki T, et al. 1Alpha,25-dihydroxyvitamin D3 promotes vascularization of the chondro-osseus junction by stimulating expression of vascular endothelial growth factor and matrix metalloproteinase 9. J Bone Min Res 2002; 17:1604-1612.
41. Zittermann A, Schleithoff SS, Koerfer R. Vitamin D and vascular calcification. Curr Opin Lipidol 2007; 18:41-46.
42. Rebsamen MC, Sun J, Norman AW, Liao JK. 1Alpha,25-dihydroxyvitamin D3 induces vascular smooth muscle cell migration via activation of phosphatidylinositol 3-kinase. Circ Res 2002; 91:17-24.
43. Hsu JJ, Tintut Y, Demer LL. Vitamin D and osteogenic differentiation in the artery wall. Clin J Am Soc Nephrol 2008; 3:1542-1547.
44. Milliner DS, Zinsmeister AR, Lieberman E, Landing B. Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int 1990; 38: 931-936.
45. Hsia J, Heiss G, Ren H, et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation 2007; 115:846-854.
46. Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117:503-511.
47. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011; 12:204-212.
48. Frostega° rd J, Ulfgren AK, Nyberg P, et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 1999; 145:33-43.
49. Mallat Z, Taleb S, Ait-Oufella H, et al. The role of adaptive T cell immunity in atherosclerosis. J Lipid Res 2009; 50:S364-S369.
50. Rigby WF, Stacy T, Fanger MW. Inhibition of T lymphocyte mitogenesis by 1,25-dihydroxyvitamin D3 (calcitriol). J Clin Invest 1984; 74:1451-1455.
51. Reichel H, Koeffler HP, Tobler A, Norman AW. 1a,25-dihydroxyvitamin D3 inhibits g-interferon synthesis by normal human peripheral blood lymphocytes. Proc Natl Acad Sci USA 1987; 84:3385-3389.
52. Bhalla AK, Amento EP, Krane SM. Differential effects of 1,25-dihydroxyvitamin D3 on human lymphocytes and monocyte/macrophages: inhibition of interleukin- 2 and augmentation of interleukin-1 production. Cell Immunol 1986; 98:311-322.
53. Hewison M. Vitamin D and the immune system: new perspectives on an old theme. Endocrinol Metab Clin North Am 2010; 39:365-379.
54. Shiozawa K, Shiozawa S, Shimizu S, et al. 1 alpha,25-dihydroxyvitamin D3 inhibits pokeweed mitogen-stimulated human B-cell activation: an analysis using serum-free culture conditions. Immunology 1985; 56:161-167.
55. Provvedini DM, Tsoukas CD, Deftos LJ, et al. 1 alpha,25-Dihydroxyvitamin D3- binding macromolecules in human B lymphocytes: effects on immunoglobulin production. J Immunol 1986; 136:2734-2740.
56. Krishnan AV, Feldman D. Molecular pathways mediating the anti-inflammatory effects of calcitriol: implications for prostate cancer chemoprevention and treatment. Endocr Relat Cancer 2010; 17:R19-38.
57. Equils O, Naiki Y, Shapiro AM, et al. 1,25-Dihydroxyvitamin D inhibits lipopolysaccharide-induced immune activation in human endothelial cells. Clin Exp Immunol 2006; 143:58-64.
58. Riek AE, Oh J, Bernal-Mizrachi C. 1,25(OH)2 vitamin D suppresses macrophage migration and reverses atherogenic cholesterol metabolism in type 2 diabetic patients. J Steroid Biochem Mol Biol 2013; 136:309-312.
59. Martinesi M, Bruni S, Stio M, Treves C. 1,25-Dihydroxyvitamin D3 inhibits tumor necrosis factor-alpha-induced adhesion molecule expression in endothelial cells. Cell Biol Int 2006; 30:365-375.
60. Borst O, Mu¨nzer P, Schmid E, et al. 1,25(OH)2 vitamin D3-dependent inhibition of platelet Ca2+ signaling and thrombus formation in klotho-deficient mice. FASEB J 2014; 28:2108-2119.
61. Stach K, Ka¨lsch AI, Nguyen XD, et al. 1a,25-dihydroxyvitamin D3 attenuates platelet activation and the expression of VCAM-1 and MT1-MMP in human endothelial cells. Cardiology 2011; 118:107-115.
62. Sung CC, Liao MT, Lu KC, Wu CC. Role of vitamin D in insulin resistance. J Biomed Biotechnol 2012; 2012:634195.
63. Norman AW, Frankel BJ, Heldt AM, Grodsky GM. Vitamin D deficiency inhibits pancreatic secretion of insulin. Science 1980; 209:823-825.
64. Kayaniyil S, Retnakaran R, Harris SB, et al. Prospective associations of vitamin D with b-cell function and glycemia. The prospective metabolism and islet cell evaluation (PROMISE) cohort study. Diabetes 2011; 60:2947-2953.
65. Pittas AG, Dawson-Hughes B, Li T, et al. Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care 2006; 29:650-656.
66. Takiishi T, Gysemans C, Bouillon R, Mathieu C. Vitamin D and diabetes. Endocrinol Metab Clin North Am 2010; 39:419-446.
67. Ponda MP, Huang X, Odeh MA, et al. Vitamin D may not improve lipid levels: a serial clinical laboratory data study. Circulation 2012; 126:270-277.
68. Burgess ED, Hawkins RG, Watanabe M. Interaction of 1,25-dihydroxyvitamin D and plasma renin activity in high renin essential hypertension. Am J Hypertens 1990; 3:903-905.
69. Resnick LM, Muller FB, Laragh JH. Calcium-regulating hormones in essential hypertension relation to plasma renin activity and sodium metabolism. Ann Intern Med 1986; 105:649-654.
70. Tomaschitz A, Pilz S, Ritz E, et al. Independent association between 1,25- dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Clin Chim Acta 2010; 411:1354-1360.
71. Yuan W, Pan W, Kong J, et al. 1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem 2007; 282:29821-29830.
72. Fitzpatrick LA, Bilezikian JP, Silverberg SJ. Parathyroid hormone and the cardiovascular system. Curr Osteoporos Rep 2008; 6:77-83.
73. Fliser D, Franek E, Fode P, et al. Subacute infusion of physiological doses of parathyroid hormone raises blood pressure in humans. Nephrol Dial Transplant 1997; 12:933-938.
74. Deb DK, Chen Y, Zhang Z, et al. 1,25-Dihydroxyvitamin D3 suppresses high glucose-induced angiotensinogen expression in kidney cells by blocking the NF-{kappa}B pathway. Am J Physiol Renal Physiol 2009; 296:F1212-1218.
75. Gro¨ber U, Spitz J, Reichrath J, et al. Vitamin D: update 2013: from rickets prophylaxis to general preventive healthcare. Dermatoendocrinol 2013; 5:331-347.
76. Wacker M, Holick MF. Sunlight and Vitamin D: a global perspective for health. Dermatoendocrinol 2013; 5:51-108.
77. Clemens TL, Adams JS, Henderson SL, et al. Increased skin pigment reduces the capacity of skin to synthesise vitamin D3. Lancet 1982; 1:74-76.
78. Pramyothin P, Holick MF. Vitamin D supplementation. Curr Opin Gastroenterol 2012; 282:139-150.
79. Institute of Medicine, Food and Nutrition Board. Dietary reference intakes for calcium and Vitamin D. Washington, DC: National Academy Press; 2010.
80. Bouillon R, Van Schoor NM, Gielen E, et al. Optimal vitamin D status: a critical analysis on the basis of evidence-based medicine. J Clin Endocrinol Metab 2013; 98:E1283-E1304.
81. Holick MF, Matsuoka LY, Wortsman J. Age, vitamin D, and solar ultraviolet. Lancet 1989; 2:1104-1105.
82. Heaney RP. Barriers to optimizing vitamin D3 intake for the elderly. J Nutr 2006; 136:1123-1125.